Efficacy of ustekinumab in palmoplantar psoriasis

Dermatology

Volumn 221, Issue 4, 2010, Pages 321-323

  Livideanu, C Bulai ^a   Lahfa, M ^a   Mazereeuw Hautier, J ^a   Paul, C ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Interleukin 12 to 23; Palmoplantar psoriasis; Stelara ; Ustekinumab

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB; VITAMIN D DERIVATIVE;

ADULT; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LETTER; LOW DRUG DOSE; MALE; MONOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PUSTULOSIS PALMOPLANTARIS; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; METHOTREXATE; OBESITY; PSORIASIS; SMOKING; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS; VITAMIN D;

EID: 78650966609     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320961     Document Type: Letter

References (5)

1. Farber EM, Nall L: Nonpustular palmoplantar psoriasis. Cutis 1992; 50: 407-410.
2. Pettey A, Balkrishnan R, Rapp SR, et al: Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271-275.
3. Leonardi CL, Kimball AB, Papp KA, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
4. Papp KA, Langley RG, Lebwohl M, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
5. Gerdes S, Franke J, Domm S, Mrowietz U: Ustekinumab in the treatment of palmo-plantar pustulosis. Br J Dermatol 2010, E-pub ahead of print.